FIG: This study is evaluating whether a new approach to imaging (FET-PET scans) will lead to more accurate assessment and management of brain cancerA prospective, multicentre trial evaluating the use of O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography (FET-PET) imaging in radiotherapy planning and clinical management of people with glioblastoma.

Summary

Imaging plays a key role in diagnosis, radiation therapy planning and monitoring of the treatment response of glioblastoma (GBM). The current standard of care with respect to imaging is MRI scans. An alternate form of imaging has been developed using Positron Emission Tomography (PET), where tumours can be imaged by utilising a newer radiotracer (FET) which detects whether tumour cells are active. All participants in this study will continue their usual care, and undergo additional FET-PET scans following chemo-radiation treatment, and at the time of subsequent suspected progression of disease. Participants will be allocated into two groups. Group 1 will receive a total of 3 FET-PET scans. FET-PET scan 1 is done at the time of post-operative radiation therapy planning. Both Groups 1 and 2 will receive FET-PET scan2 four weeks after radiation therapy is complete and FET-PET scan 3 will be received post chemotherapy once changes are seen on routine MRIs.

Treatment Type

Radiotherapy